Skip to main content

Advertisement

SpringerLink
Log in

The prevalence and clinical significance of anti-PUF60 antibodies in patients with idiopathic inflammatory myopathy

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Autoantibodies against poly-U-binding factor 60 kDa protein (PUF60) have been reported in Caucasian dermatomyositis (DM) patients. However, their clinical significance in idiopathic inflammatory myopathy (IIM) remains to be fully clarified. Our objective was to analyze the prevalence and clinical significance of anti-PUF60 antibodies in a large cohort of Chinese IIM patients. In our study, 388 IIM patients, 301 disease controls, and 167 healthy controls (HCs) were involved. An enzyme-linked immunosorbent assay (ELISA) was developed to detect serum anti-PUF60 levels and was validated using immunoblotting methods. Unpaired Mann-Whitney U test and Spearman correlation analysis were used when appropriate. Anti-PUF60 antibodies were observed in IIM patients at a frequency of 10.6% (41/388). Subgrouping analysis revealed that the prevalence of anti-PUF60 antibodies was 10% in DM, 5.5% in polymyositis (PM), 10% in immune-mediated necrotizing myositis (IMNM), and 26.5% in myositis-overlap syndrome. Anti-PUF60 antibodies were also observed in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and Sjögren’s syndrome (SS) patients at a positive rate of 17.3, 14.5, and 10.1% respectively. Intriguingly, anti-PUF60 antibodies were frequently observed in clinically amyopathic dermatomyositis (CADM) patients and DM patients without currently known myositis autoantibodies. Furthermore, DM patients with anti-PUF60 antibodies had higher prevalence of skin ulcerations. Moreover, longitudinal investigation in eight DM patients with anti-PUF60 antibodies revealed that the antibodies levels decreased with disease remission. Anti-PUF60 antibodies were nonspecific for myositis, since they could be detected in other rheumatic diseases. Further investigation of anti-PUF60 antibodies may reveal shared pathogenic pathways in systemic autoimmune disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jones J, Wortmann R (2015) Idiopathic inflammatory myopathies-a review. Clin Rheumatol 34:839–844. https://doi.org/10.1007/s10067-015-2891-4

    Article  PubMed  Google Scholar 

  2. Lu X, Peng Q, Wang G (2015) Discovery of new biomarkers of idiopathic inflammatory myopathy. Clin Chim Acta 444:117–125. https://doi.org/10.1016/j.cca.2015.02.007

    Article  CAS  PubMed  Google Scholar 

  3. Gunawardena H, Betteridge ZE, McHugh NJ (2008) Newly identified autoantibodies: relationship to idiopathic inflammatory myopathy subsets and pathogenesis. Curr Opin Rheumatol 20:675–680. https://doi.org/10.1097/BOR.0b013e328313bff4

    Article  CAS  PubMed  Google Scholar 

  4. Fiorentino DF, Presby M, Baer AN, Petri M, Rieger KE, Soloski M, Rosen A, Mammen AL, Christopher-Stine L, Casciola-Rosen L (2016) PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjogren's syndrome. Ann Rheum Dis 75:1145–1151. https://doi.org/10.1136/annrheumdis-2015-207509

    Article  CAS  PubMed  Google Scholar 

  5. Albrecht I, Wick C, Hallgren A, Tjarnlund A, Nagaraju K, Andrade F, Thompson K, Coley W, Phadke A, Diaz-Gallo LM et al (2015) Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies. J Clin Invest 125:4612–4624. https://doi.org/10.1172/jci81031

    Article  PubMed  PubMed Central  Google Scholar 

  6. Corsini L, Hothorn M, Stier G, Rybin V, Scheffzek K, Gibson TJ, Sattler M (2009) Dimerization and protein binding specificity of the U2AF homology motif of the splicing factor Puf60. J Biol Chem 284:630–639. https://doi.org/10.1074/jbc.M805395200

    Article  CAS  PubMed  Google Scholar 

  7. Yang H, Peng Q, Yin L, Li S, Shi J, Zhang Y, Lu X, Shu X, Zhang S, Wang G (2017) Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res Ther 19:259. https://doi.org/10.1186/s13075-017-1469-8

    Article  PubMed  PubMed Central  Google Scholar 

  8. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347. https://doi.org/10.1056/nejm197502132920706

    Article  CAS  PubMed  Google Scholar 

  9. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, Vencovsky J, de Visser M, Hughes RA (2004) 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 14:337–345. https://doi.org/10.1016/j.nmd.2004.02.006

    Article  PubMed  Google Scholar 

  10. Ioannou Y, Sultan S, Isenberg DA (1999) Myositis overlap syndromes. Curr Opin Rheumatol 11:468–474

    Article  CAS  PubMed  Google Scholar 

  11. Bailey EE, Fiorentino DF (2014) Amyopathic dermatomyositis: definitions, diagnosis, and management. Curr Rheumatol Rep 16:465. https://doi.org/10.1007/s11926-014-0465-0

    Article  PubMed  Google Scholar 

  12. Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, Oddis C, Pilkington C, Plotz P, Scott D, Vencovsky J, Cooper R, Rider L, Miller F, International Myositis and Clinical Studies Group (IMACS) (2004) International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43:49–54. https://doi.org/10.1093/rheumatology/keg427

    Article  CAS  Google Scholar 

  13. Ge Y, Lu X, Peng Q, Shu X, Wang G (2015) Clinical characteristics of Anti-3-Hydroxy-3-Methylglutaryl coenzyme a Reductase antibodies in Chinese patients with idiopathic inflammatory myopathies. PLoS One 10:e0141616. https://doi.org/10.1371/journal.pone.0141616

    Article  PubMed  PubMed Central  Google Scholar 

  14. Corsini L, Sattler M (2008) Backbone assignment of the UHM domain of Puf60 free and bound to five ligands. Biomol NMR Assign 2:211–214. https://doi.org/10.1007/s12104-008-9123-7

    Article  CAS  PubMed  Google Scholar 

  15. Kobayashi S, Hoshino T, Hiwasa T, Satoh M, Rahmutulla B, Tsuchida S, Komukai Y, Tanaka T, Matsubara H, Shimada H, Nomura F, Matsushita K (2016) Anti-FIRs (PUF60) auto-antibodies are detected in the sera of early-stage colon cancer patients. Oncotarget 7:82493–82503. https://doi.org/10.18632/oncotarget.12696

    PubMed  PubMed Central  Google Scholar 

  16. Matsushita K, Tomonaga T, Shimada H, Shioya A, Higashi M, Matsubara H, Harigaya K, Nomura F, Libutti D, Levens D, Ochiai T (2006) An essential role of alternative splicing of c-myc suppressor FUSE-binding protein-interacting repressor in carcinogenesis. Cancer Res 66:1409–1417. https://doi.org/10.1158/0008-5472.can-04-4459

    Article  CAS  PubMed  Google Scholar 

  17. Muro Y, Sugiura K, Akiyama M (2016) Cutaneous manifestations in Dermatomyositis: key clinical and serological features-a comprehensive review. Clin Rev Allergy Immunol 51:293–302. https://doi.org/10.1007/s12016-015-8496-5

    Article  PubMed  Google Scholar 

  18. Narang NS, Casciola-Rosen L, Li S, Chung L, Fiorentino DF (2015) Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease. Arthritis Care Res (Hoboken) 67:667–672. https://doi.org/10.1002/acr.22498

    Article  CAS  Google Scholar 

  19. Gono T, Kawaguchi Y, Kuwana M, Sugiura T, Furuya T, Takagi K, Ichida H, Katsumata Y, Hanaoka M, Ota Y, Yamanaka H (2012) Brief report: association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum 64:3736–3740. https://doi.org/10.1002/art.34657

    Article  CAS  PubMed  Google Scholar 

  20. Rothwell S, Cooper RG, Lamb JA, Chinoy H (2013) Entering a new phase of immunogenetics in the idiopathic inflammatory myopathies. Curr Opin Rheumatol 25:735–741. https://doi.org/10.1097/01.bor.0000434676.70268.66

    Article  CAS  PubMed  Google Scholar 

  21. O'Hanlon TP, Rider LG, Mamyrova G, Targoff IN, Arnett FC, Reveille JD, Carrington M, Gao X, Oddis CV, Morel PA, Malley JD, Malley K, Shamim EA, Chanock SJ, Foster CB, Bunch T, Reed AM, Love LA, Miller FW (2006) HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum 54:3670–3681. https://doi.org/10.1002/art.22205

    Article  PubMed  Google Scholar 

  22. Chinoy H, Payne D, Poulton KV, Fertig N, Betteridge Z, Gunawardena H, Davidson JE, Oddis CV, McHugh NJ, Wedderburn LR et al (2009) HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PM-Scl antibody positive idiopathic inflammatory myopathy. Rheumatology (Oxford) 48:1213–1217. https://doi.org/10.1093/rheumatology/kep248

    Article  CAS  Google Scholar 

  23. Tieu J, Lundberg IE, Limaye V (2016) Idiopathic inflammatory myositis. Best Pract Res Clin Rheumatol 30:149–168. https://doi.org/10.1016/j.berh.2016.04.007

    Article  PubMed  Google Scholar 

  24. Ghirardello A, Borella E, Beggio M, Franceschini F, Fredi M, Doria A (2014) Myositis autoantibodies and clinical phenotypes. Auto Immun Highlights 5:69–75. https://doi.org/10.1007/s13317-014-0060-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Sordet C, Goetz J, Sibilia J (2006) Contribution of autoantibodies to the diagnosis and nosology of inflammatory muscle disease. Joint Bone Spine 73:646–654. https://doi.org/10.1016/j.jbspin.2006.04.005

    Article  CAS  PubMed  Google Scholar 

  26. Belizna C, Henrion D, Beucher A, Lavigne C, Ghaali A, Levesque H (2010) Anti-Ku antibodies: clinical, genetic and diagnostic insights. Autoimmun Rev 9:691–694. https://doi.org/10.1016/j.autrev.2010.05.020

    Article  CAS  PubMed  Google Scholar 

  27. Mahler M, Raijmakers R (2007) Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev 6:432–437. https://doi.org/10.1016/j.autrev.2007.01.013

    Article  CAS  PubMed  Google Scholar 

  28. Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, Domsic R, Ascherman DP (2007) Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 56:3125–3131. https://doi.org/10.1002/art.22865

    Article  CAS  PubMed  Google Scholar 

  29. Sato S, Kuwana M, Fujita T, Suzuki Y (2013) Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol 23:496–502. https://doi.org/10.1007/s10165-012-0663-4

    Article  CAS  PubMed  Google Scholar 

  30. Aggarwal R, Oddis CV, Goudeau D, Fertig N, Metes I, Stephens C, Qi Z, Koontz D, Levesque MC (2015) Anti-signal recognition particle autoantibody ELISA validation and clinical associations. Rheumatology (Oxford) 54:1194–1199. https://doi.org/10.1093/rheumatology/keu436

    Article  CAS  Google Scholar 

  31. Ge Y, Lu X, Shu X, Peng Q, Wang G (2017) Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts. Sci Rep 7:188. https://doi.org/10.1038/s41598-017-00240-6

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Natural Science Foundation of China (81701615, 91542121, 81571603), the Capital Foundation of Medical Developments (2016-2-4063), and the Science and Technology Commission Foundation of Beijing (Z151100004015143, Z171100001017208).

Author information

Authors and Affiliations

  1. Department of Rheumatology, Beijing Key Lab for Immune-Mediated Inflammatory Diseases, China-Japan Friendship Hospital, Yinghua East Road, Chaoyang District, Beijing, 100029, China

    Ya-Mei Zhang, Han-Bo Yang, Jing-Li Shi, He Chen, Xiao-Ming Shu, Xin Lu, Guo-Chun Wang & Qing-Lin Peng

  2. Graduate School of Peking Union Medical College, Beijing, 100730, China

    Ya-Mei Zhang & Guo-Chun Wang

Authors
  1. Ya-Mei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Han-Bo Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jing-Li Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. He Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiao-Ming Shu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xin Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Guo-Chun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Qing-Lin Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qing-Lin Peng.

Ethics declarations

This study was approved by the Ethics Committee of the Institutional Review Board at the China-Japan Friendship Hospital (reference number: 2016-117). All the participants provided written informed consent for the collection of samples and subsequent analysis.

Disclosures

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, YM., Yang, HB., Shi, JL. et al. The prevalence and clinical significance of anti-PUF60 antibodies in patients with idiopathic inflammatory myopathy. Clin Rheumatol 37, 1573–1580 (2018). https://doi.org/10.1007/s10067-018-4031-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-018-4031-4

Keywords

Search

Navigation